Clover Biopharmaceuticals, Chengdu, China.
Key Laboratory of Animal Models and Human Disease Mechanisms of the Chinese Academy of Sciences, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, China.
Nat Commun. 2021 Mar 1;12(1):1346. doi: 10.1038/s41467-021-21634-1.
SARS-CoV-2 is the underlying cause for the COVID-19 pandemic. Like most enveloped RNA viruses, SARS-CoV-2 uses a homotrimeric surface antigen to gain entry into host cells. Here we describe S-Trimer, a native-like trimeric subunit vaccine candidate for COVID-19 based on Trimer-Tag technology. Immunization of S-Trimer with either AS03 (oil-in-water emulsion) or CpG 1018 (TLR9 agonist) plus alum adjuvants induced high-level of neutralizing antibodies and Th1-biased cellular immune responses in animal models. Moreover, rhesus macaques immunized with adjuvanted S-Trimer were protected from SARS-CoV-2 challenge compared to vehicle controls, based on clinical observations and reduction of viral loads in lungs. Trimer-Tag may be an important platform technology for scalable production and rapid development of safe and effective subunit vaccines against current and future emerging RNA viruses.
SARS-CoV-2 是 COVID-19 大流行的根本原因。与大多数包膜 RNA 病毒一样，SARS-CoV-2 使用三聚体表面抗原进入宿主细胞。在这里，我们描述了 S-Trimer，这是一种基于三聚体标签技术的 COVID-19 新型三聚体亚单位候选疫苗。使用 AS03（油包水乳剂）或 CpG 1018（TLR9 激动剂）加明矾佐剂免疫 S-Trimer，在动物模型中诱导了高水平的中和抗体和 Th1 偏向的细胞免疫反应。此外，与载体对照组相比，用佐剂 S-Trimer 免疫的恒河猴在 SARS-CoV-2 攻毒后得到了保护，这是基于临床观察和肺部病毒载量的减少。三聚体标签可能是一种重要的平台技术，可用于大规模生产和快速开发针对当前和未来新兴 RNA 病毒的安全有效的亚单位疫苗。
Zotero 插件
